Announcements Trials
Browse Landscape

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Observational 3Interventional 2

Sponsor

Cancer Type

Gynecologic 13Tumor-Agnostic 11Gastrointestinal 11Thoracic 8Genitourinary 8Other hematologic neoplasm 6Lymphoid 5Dermatologic 5Breast 5Head & Neck 4Plasma cell 3Other solid neoplasm 3NET 3Endocrine 3CNS 3Sarcoma 2Myeloid 2Classical hematology 2

Conditions

Neuroendocrine Tumors 3

Interventions

lutetium Lu 177 dotatate 6Magnetic Resonance Spectroscopy 3Data Collection 3telotristat ethyl 2surufatinib 2Somatostatin 2Positron-Emission Tomography 2Everolimus 2Drug Therapy 2Biopsy 2lanreotide 1copper dotatate CU-64 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Sunitinib 1Sorafenib 1Salvage Therapy 1Radionuclide Imaging 1Radiomics 1Radiofrequency Ablation 1Quality of Life 1Plastic Surgery Procedures 1Phlebotomy 1Patient Reported Outcome Measures 1Octreotide 1Molecular Diagnostic Techniques 1Lutetium-177 1Lutetium 1Liver Transplantation 1Laparoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × Data Collection × NET × Clear all
NCT03562091 2020-08-28

OPERA

Ipsen

Completed
115 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03112694 2020-06-02

Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors

Ipsen

Completed
93 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03220087 2018-12-21

RECOSY

Ipsen

Completed
142 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡